Polymyalgia Rheumatica Treatment Market Size in the 7MM is projected to grow by 2034, estimates DelveInsight

DelveInsight's "Polymyalgia Rheumatica Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Polymyalgia Rheumatica, historical and forecasted epidemiology and the Polymyalgia Rheumatica market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Polymyalgia Rheumatica Market Report

* In December 2025, Novartis Pharmaceuticals conducted a study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica. The study will consist of an up to 4-week screening period, an up to 2-year Treatment Period which includes two Treatment Periods, and a 16-week treatment-free follow-up period (20 weeks post last dose of secukinumab).
* According to the analysis, the number of individuals living with polymyalgia rheumatica in the US is projected to grow during the forecast period (2025-2034). This rise stems from an aging population, increased life expectancy among older adults, and greater recognition of the condition in routine health assessments.
* According to the secondary research, the age-adjusted prevalence of polymyalgia rheumatica in the US is approximately 701 cases per 100,000 individuals aged 50 years and older.
* As per the secondary research, higher rates in females at 870 per 100,000 and in males at 508 per 100,000.
* As per the secondary research, approximately 15% of patients with PMR develop giant cell arteritis (GCA), and 40-50% of patients with GCA have associated PMR.
* The leading Polymyalgia Rheumatica Companies such as Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharmaceuticals, Chugai Pharma, AbbVie, Janssen Research & Development, Sint Maartenskliniek , and others
* Promising Polymyalgia Rheumatica Therapies such as Tocilizumab, Abatacept, Baricitinib, Secukinumab, ABBV-154, SPI-62, TCZ, Upadacitinib, Guselkumab, Rituximab , and others

Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Polymyalgia Rheumatica Treatment Market Size [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Polymyalgia Rheumatica Epidemiology Segmentation in the 7MM

* Total Prevalent Cases of Polymyalgia Rheumatica
* Total Diagnosed Prevalent Cases of Polymyalgia Rheumatica
* Gender-specific Diagnosed Prevalent Cases of Polymyalgia Rheumatica
* Treated Cases of Polymyalgia Rheumatica

Download the report to understand which factors are driving Polymyalgia Rheumatica epidemiology trends @ Polymyalgia Rheumatica Prevalence [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Polymyalgia Rheumatica Marketed Drugs

* KEVZARA (sarilumab): Regeneron Pharmaceuticals

KEVZARA (sarilumab) is a fully human monoclonal antibody developed by Regeneron and Sanofi that targets and inhibits both soluble and membrane-bound interleukin-6 receptors (IL6R). It is the first and only biologic approved by the FDA specifically for adults with polymyalgia rheumatica who are inadequate responders to corticosteroids or cannot tolerate tapering. By blocking IL6 signaling, KEVZARA significantly reduces inflammation and disease activity, enabling more patients to achieve steroid-free remission, with supportive evidence from the Phase III SAPHYR trial showing nearly threefold higher sustained remission rates compared to placebo

Polymyalgia Rheumatica Emerging Drugs

* SPI-47: Sparrow Pharmaceuticals

SPI-47, is an investigational oral treatment for polymyalgia rheumatica (PMR) that combines low-dose prednisolone with clofutriben (SPI-62), a targeted 11-HSD1 inhibitor. This combination is intended to deliver the anti-inflammatory benefits of steroids while minimizing their long-term side effects by reducing cortisol activation in tissues such as bone, muscle, and liver. Currently in Phase IIa trials, SPI-47 is being studied as a potential steroid-sparing therapy to improve the safety and effectiveness of PMR treatment.

* COSENTYX (secukinumab): Novartis

Secukinumab developed by Novartis is a fully human IgG1 monoclonal antibody that neutralizes interleukin17A (IL17A), a key cytokine driving inflammation. It is now being investigated as a treatment for polymyalgia rheumatica (PMR). In PMR, secukinumab is being studied for its potential to reduce inflammation and lower dependence on corticosteroids. A Phase III clinical trial (REPLENISH) is evaluating its effectiveness in achieving steroid-free remission in patients with relapsing PMR when combined with a short course of glucocorticoids.

Discover the future of Polymyalgia Rheumatica treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Polymyalgia Rheumatica Market Drivers and Barriers [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Polymyalgia Rheumatica Companies

Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharmaceuticals, Chugai Pharma, AbbVie, Janssen Research & Development, Sint Maartenskliniek , and others

Polymyalgia Rheumatica Market Outlook

Treatment options for polymyalgia rheumatica primarily focus on controlling inflammation and relieving symptoms, with low-dose corticosteroids, such as prednisone, being the standard and most effective first-line therapy. While newer insights have emerged such as the role of IL-6 in inflammation major therapeutic breakthroughs have been limited, and most treatment strategies still revolve around careful steroid tapering over months to years. In patients who relapse frequently or are steroid-intolerant, off-label use of immunosuppressants like methotrexate or biologics such as KEVZARA (sarilumab) is considered.

Scope of the Polymyalgia Rheumatica Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Polymyalgia Rheumatica Companies- Roche, Bristol Myers Squibb, Eli-lilly, Novartis, AbbVie, Sparrow Pharmaceuticals, Chugai Pharma, AbbVie, Janssen Research & Development, Sint Maartenskliniek , and others
* Polymyalgia Rheumatica Therapies- Tocilizumab, Abatacept, Baricitinib, Secukinumab, ABBV-154, SPI-62, TCZ, Upadacitinib, Guselkumab, Rituximab , and others
* Polymyalgia Rheumatica Therapeutic Assessment: Polymyalgia Rheumatica current marketed and Polymyalgia Rheumatica emerging therapies
* Polymyalgia Rheumatica Market Dynamics: Polymyalgia Rheumatica market drivers and Polymyalgia Rheumatica market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Polymyalgia Rheumatica Unmet Needs, KOL's views, Analyst's views, Polymyalgia Rheumatica Market Access and Reimbursement

From market size to emerging drugs, find it all in our latest report. Read now! @ Polymyalgia Rheumatica Ongoing Clinical Trials Analysis [https://www.delveinsight.com/sample-request/polymyalgia-rheumatica-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Polymyalgia Rheumatica Market Overview at a Glance

4. Polymyalgia Rheumatica Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Polymyalgia Rheumatica: Disease Background and Overview

8. Polymyalgia Rheumatica Epidemiology and Patient Population

9. Patient Journey

10. Polymyalgia Rheumatica Marketed Drugs

11. Polymyalgia Rheumatica Emerging Drugs

12. Polymyalgia Rheumatica: Market Analysis

13. Key Opinion Leaders' Views

14. Polymyalgia Rheumatica SWOT Analysis

15. Polymyalgia Rheumatica Unmet Needs

16. Polymyalgia Rheumatica Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=polymyalgia-rheumatica-treatment-market-size-in-the-7mm-is-projected-to-grow-by-2034-estimates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/polymyalgia-rheumatica-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.